Human RAGE antibody protects against AGE-mediated podocyte dysfunction.
暂无分享,去创建一个
[1] T. Reinheckel,et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. , 2011, The Journal of clinical investigation.
[2] E. Salido,et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.
[3] H. Hammes,et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. , 2011, Journal of the American Society of Nephrology : JASN.
[4] K. Endlich,et al. AlphaV-integrins mediate the mechanoprotective action of osteopontin in podocytes. , 2011, American journal of physiology. Renal physiology.
[5] U. Haug,et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] C. Ahn,et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] P. Nawroth,et al. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications , 2009, Diabetologia.
[8] M. Zeier,et al. RAGE expression in the human peritoneal membrane. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] M. Zeier,et al. Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure , 2008, European journal of clinical investigation.
[10] P. Carmeliet,et al. Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.
[11] K. Pawlaczyk,et al. Effect of peritoneal dialysis on renal morphology and function. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Yeong-Hoon Kim,et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] Yasuhiko Tomino,et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling , 2006, Nature Cell Biology.
[14] M. Zeier,et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. , 2005, Journal of the American Society of Nephrology : JASN.
[15] D. Clapham,et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function , 2005, Nature Genetics.
[16] R. Miller,et al. WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. , 2005, American journal of physiology. Renal physiology.
[17] P. Gane,et al. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] M. Cooper,et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. , 2004, The American journal of pathology.
[19] R. Tilton,et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. , 2003, Journal of the American Society of Nephrology : JASN.
[20] F. Dekker,et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] A. Tauer,et al. Formation of advanced glycation end products during CAPD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] C. Wanner,et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? , 2003, Kidney international.
[23] M. Cooper,et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. , 2002, Diabetes.
[24] Alan W. Stitt,et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.
[25] M. O'hare,et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. , 2002, Journal of the American Society of Nephrology : JASN.
[26] P. Blake,et al. Peritoneal dialysis adequacy and risk of death , 2001, Current opinion in nephrology and hypertension.
[27] D. Churchill,et al. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. , 2001, Journal of the American Society of Nephrology : JASN.
[28] D. Uttenweiler,et al. Podocytes respond to mechanical stress in vitro. , 2001, Journal of the American Society of Nephrology : JASN.
[29] A. Wieslander,et al. Biological Significance of Reducing Glucose Degradation Products in Peritoneal Dialysis Fluids , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[30] V. D’Agati,et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.
[31] Z. Makita,et al. Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.
[32] A. Wieslander,et al. Heat Sterilization of Glucose-Containing Fluids for Peritoneal Dialysis: Biological Consequences of Chemical Alterations , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.